In this simulation-based economic evaluation of 250,000 statin-eligible US adults without atherosclerotic cardiovascular disease, using apolipoprotein B targets to guide lipid-lowering therapy intensification yielded more quality-adjusted life-years than low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol targets. Apolipoprotein B-guided therapy was highly cost-effective, with an incremental cost-effectiveness ratio of $30,300 per quality-adjusted life-year gained, supporting its use for primary prevention.

Source: JAMA